PHARMAC: Newly Funded Medicine To Benefit 110 More People With Thyroid, Liver, And Kidney Cancer Dr David Hughes, Pharmac’s ...

Pharmac is funding Lisdexamfetamine for ADHD and narcolepsy, benefiting more than 6000 people from December. Pharmac is ...

Pharmac has decided to fund an at-home low sensitivity test kit that confirms a pregnancy has ended following a medical abortion. The urine test kit (branded as CheckToP) detects the levels of ...

Pharmac is set to fund an at-home testing kit to find out if a pregnancy termination has been successful. The testing kit ...

Prime Minister Christopher Luxon today made a formal apology in the House to people abused while in care. Survivors and advocates have criticised the decision to hold the government's abuse in care ...

Pharmac has decided to disestablish it's Māori advisory group. In a statement, the chairperson of the drug funding agency ...

“Onco360 is grateful for the opportunity to partner with the team at Genentech and become a specialty pharmacy provider for Itovebi ™ ,” said Benito Fernandez. “We are proud to add another treatment ...

Advocacy group Aroreretini Aotearoa, says the changes will improve productivity for the ADHD community, by almost 57-million-dollars. Chief medical officer David Hughes says it will streamline ...

Pharmac has announced it'll fund new stimulant medicine lisdexamfetamine from December. The medicine -- branded as Vyvanse -- is taken once a day. Chief medical officer, David Hughes, says it's a ...

From 1 December 2024, Pharmac is also removing the renewal criteria for methylphenidate, dexamfetamine and modafinil, medicines used to treat ADHD and narcolepsy. This means that once an initial ...

On the other hand, efforts to manage these costs through preauthorizations – reviewing certain treatments and procedures to confirm they are medically necessary prior to receiving services – have been ...

Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...